Analysts at Sidoti initiated coverage on shares of Inogen Inc (NASDAQ:INGN) in a research note issued to investors on Tuesday, The Fly reports. The firm set a “neutral” rating on the medical technology company’s stock.

Several other research analysts also recently commented on INGN. Needham & Company LLC raised their target price on Inogen from $78.00 to $83.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, March 1st. Stifel Nicolaus raised their target price on Inogen to $65.00 in a research note on Wednesday, March 1st. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $77.00 price target for the company in a research report on Thursday, March 2nd. TheStreet upgraded Inogen from a “c” rating to a “b-” rating in a research report on Tuesday, February 28th. Finally, JPMorgan Chase & Co. set a $78.00 price target on Inogen and gave the company a “buy” rating in a research report on Wednesday, March 1st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $72.60.

Shares of Inogen (NASDAQ:INGN) traded down 1.340% on Tuesday, reaching $75.741. The company’s stock had a trading volume of 99,068 shares. Inogen has a 12 month low of $43.16 and a 12 month high of $79.94. The stock has a market cap of $1.55 billion, a P/E ratio of 78.084 and a beta of 1.07. The firm’s 50-day moving average price is $74.67 and its 200-day moving average price is $66.21.

Inogen (NASDAQ:INGN) last issued its earnings results on Tuesday, February 28th. The medical technology company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.10 by $0.15. Inogen had a return on equity of 9.59% and a net margin of 7.70%. The business earned $50.85 million during the quarter, compared to the consensus estimate of $46.19 million. During the same quarter last year, the company earned $0.19 EPS. The firm’s revenue was up 25.7% compared to the same quarter last year. On average, analysts forecast that Inogen will post $1.04 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at http://www.dailypolitical.com/2017/04/18/inogen-inc-ingn-receives-new-coverage-from-analysts-at-sidoti.html.

In other news, EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction dated Wednesday, March 15th. The stock was sold at an average price of $73.85, for a total transaction of $184,625.00. Following the completion of the sale, the executive vice president now owns 4,833 shares in the company, valued at approximately $356,917.05. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Brenton Taylor sold 3,750 shares of Inogen stock in a transaction dated Tuesday, February 28th. The shares were sold at an average price of $70.07, for a total value of $262,762.50. Following the sale, the executive vice president now owns 31,851 shares of the company’s stock, valued at approximately $2,231,799.57. The disclosure for this sale can be found here. Company insiders own 5.18% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Inogen during the third quarter worth about $211,000. Municipal Employees Retirement System of Michigan increased its stake in shares of Inogen by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 3,220 shares of the medical technology company’s stock worth $193,000 after buying an additional 50 shares during the period. New York State Common Retirement Fund increased its stake in shares of Inogen by 2.0% in the third quarter. New York State Common Retirement Fund now owns 211,440 shares of the medical technology company’s stock worth $12,665,000 after buying an additional 4,225 shares during the period. BlackRock Fund Advisors increased its stake in shares of Inogen by 11.5% in the third quarter. BlackRock Fund Advisors now owns 1,179,565 shares of the medical technology company’s stock worth $70,656,000 after buying an additional 121,397 shares during the period. Finally, BlackRock Investment Management LLC increased its stake in shares of Inogen by 0.7% in the third quarter. BlackRock Investment Management LLC now owns 67,727 shares of the medical technology company’s stock worth $4,057,000 after buying an additional 449 shares during the period.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

5 Day Chart for NASDAQ:INGN

The Fly

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.